Severe colitis while responding to ipilimumab in metastatic melanoma

Acta Oncologica

Volumn 51, Issue 6, 2012, Pages 805-807

  Slingerland, Marije ^a   Nortier, Johan W R ^a   Veenendaal, Roeland A ^a   Kapiteijn, Ellen ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; GLYCOPROTEIN GP 100; INFLIXIMAB; IPILIMUMAB; MESALAZINE; PEPTIDE VACCINE; PLACEBO; PREDNISONE;

ABDOMINAL PAIN; ADULT; APPETITE; CANCER PATIENT; CANCER SURVIVAL; CASE REPORT; COLITIS; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENCE; DIARRHEA; DISEASE SEVERITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; LETTER; LIVER METASTASIS; MELANOMA; NAUSEA; NECROTIZING FASCIITIS; OVERALL SURVIVAL; PANCOLITIS; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; TREATMENT RESPONSE; TUMOR IMMUNITY; VOMITING;

ANTIBODIES, MONOCLONAL; COLITIS; FEMALE; HUMANS; LIVER NEOPLASMS; MELANOMA; MIDDLE AGED; PROGNOSIS;

EID: 84863863294     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.682630     Document Type: Letter

References (10)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
3. Hanaizi Z, van Zwieten-Boot B, Calvo G. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2012;48:237-42.
4. Graziani G, Tentori L, Navarra P. Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res Epub 2011 Sep 10.
5. Lin R, Yellin MJ, Lowy I, Safferman A, Chin K, Ibrahim R. An analysis of the effectiveness of specific guidelines for the management of ipilimumab mediated diarrhea/colitis: Prevention of intestinal perforation and/or colectomy. J Clin Oncol 2008;26:9063.
6. van den Eertwegh AJM, Bloemena E, Hoentjen F, van Bodegraven AA. Behandeling van auto-immuunreacties ten gevolge van een immuuntherapie met een antistof tegen CTLA-4 (ipilimumab) bij patiënten met een gemetastaseerd melanoom. Ned Tijdschr Oncol 2010;7:258-63.
7. Pennock GK, Waterfield W, Wolchok JD. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: How different are these from conventional treatment responses? Am J Clin Oncol Epub 2011 Feb 17.
8. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-9. (Pubitemid 46630658)
9. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumour regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23: 6043-53.
10. Lutzky J, Wolchok J, Hamid O, Lebbe C, Pehamberger H, Linette G, et al. Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 2009;27:9034.